DP
MREO

Diadema Partners’s Mereo BioPharma MREO Stock Holding History

Diadema Partners’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-39,400
Closed -$81.2K – 171
2025
Q3 		$81.2K Hold
39,400
– – 0.02% 122
2025
Q2 		$107K Hold
39,400
– – 0.03% 90
2025
Q1 		$88.7K Buy
+39,400
New +$111K 0.02% 98

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

Diadema Partners's MREO Position: Q2 2025 in Review

Diadema Partners sold out of Mereo BioPharma (MREO) in Q2 2025, closing a stake of 492,215 shares — an estimated $1.19M sold.

Diadema Partners first reported a position in MREO in Q1 2025 and held it in 1 quarter. The position peaked at $169K in Q1 2025. 86 funds tracked by Wall St. Rank hold MREO as of Q2 2025.

  • Diadema Partners reported no remaining Mereo BioPharma position as of Q2 2025 after selling out during the quarter.
  • Diadema Partners sold 492,215 Mereo BioPharma shares in Q2 2025, an estimated $1.19M.
  • Diadema Partners first reported a position in Mereo BioPharma in Q1 2025 and held it in 1 quarter.
  • Diadema Partners's Mereo BioPharma position peaked at $169K in Q1 2025.
  • 86 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2025.

Based on Diadema Partners's 13F filing for Q2 2025, filed 14 Aug 2025.